University of Kentucky

UKnowledge
Radiation Medicine Faculty Publications

Radiation Medicine

7-2020

A Novel and Clinically Useful Dynamic Conformal Arc (DCA)Based VMAT Planning Technique for Lung SBRT
Damodar Pokhrel
University of Kentucky, damodar.pokhrel@uky.edu

Justin Visak
University of Kentucky, justinvisak18@gmail.com

Lana Sanford
University of Kentucky

Follow this and additional works at: https://uknowledge.uky.edu/radmed_facpub
Part of the Radiation Medicine Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Pokhrel, Damodar; Visak, Justin; and Sanford, Lana, "A Novel and Clinically Useful Dynamic Conformal Arc
(DCA)-Based VMAT Planning Technique for Lung SBRT" (2020). Radiation Medicine Faculty Publications.
32.
https://uknowledge.uky.edu/radmed_facpub/32

This Article is brought to you for free and open access by the Radiation Medicine at UKnowledge. It has been
accepted for inclusion in Radiation Medicine Faculty Publications by an authorized administrator of UKnowledge.
For more information, please contact UKnowledge@lsv.uky.edu.

A Novel and Clinically Useful Dynamic Conformal Arc (DCA)-Based VMAT
Planning Technique for Lung SBRT
Digital Object Identifier (DOI)
https://doi.org/10.1002/acm2.12878

Notes/Citation Information
Published in Journal of Applied Clinical Medical Physics, v. 21, issue 7.
© 2020 The Authors
This is an open access article under the terms of the Creative Commons Attribution License, which
permits use, distribution and reproduction in any medium, provided the original work is properly cited.

This article is available at UKnowledge: https://uknowledge.uky.edu/radmed_facpub/32

Received: 23 January 2019

|

Revised: 12 March 2020

|

Accepted: 15 March 2020

DOI: 10.1002/acm2.12878

RADIATION ONCOLOGY PHYSICS

A novel and clinically useful dynamic conformal arc (DCA)‐
based VMAT planning technique for lung SBRT
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Abstract
Purpose: Volumetric modulated arc therapy (VMAT) is gaining popularity for stereo-
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tactic treatment of lung lesions for medically inoperable patients. Due to multiple
beamlets in delivery of highly modulated VMAT plans, there are dose delivery
uncertainties associated with small‐ﬁeld dosimetry error and interplay effects with
small lesions. We describe and compare a clinically useful dynamic conformal arc
(DCA)‐based VMAT (d‐VMAT) technique for lung SBRT using ﬂattening ﬁlter free
(FFF) beams to minimize these effects.
Materials and Methods: Ten solitary early‐stage I‐II non‐small‐cell lung cancer
(NSCLC) patients were treated with a single dose of 30 Gy using 3–6 non‐coplanar
VMAT arcs (clinical VMAT) with 6X‐FFF beams in our clinic. These clinically treated
plans were re‐optimized using a novel d‐VMAT planning technique. For comparison,
d‐VMAT plans were recalculated using DCA with user‐controlled ﬁeld aperture
shape before VMAT optimization. Identical beam geometry, dose calculation algorithm, grid size, and planning objectives were used. The clinical VMAT and d‐VMAT
plans were compared via RTOG‐0915 protocol compliances for conformity, gradient
indices, and dose to organs at risk (OAR). Additionally, treatment delivery efﬁciency
and accuracy were recorded.
Results: All plans met RTOG‐0915 requirements. Comparing with clinical VMAT, d‐
VMAT plans gave similar target coverage with better target conformity, tighter
radiosurgical dose distribution with lower gradient indices, and dose to OAR. Lower
total number of monitor units and small beam modulation factor reduced beam‐on
time by 1.75 min (P < 0.001), on average (maximum up to 2.52 min). Beam delivery
accuracy was improved by 2%, on average (P < 0.05) and maximum up to 6% in
some cases for d‐VMAT plans.
Conclusion: This simple d‐VMAT technique provided excellent plan quality, reduced
intermediate dose‐spillage, and dose to OAR while providing faster treatment delivery by signiﬁcantly reducing beam‐on time. This novel treatment planning approach
will improve patient compliance along with potentially reducing intrafraction motion
error. Moreover, with less MLC modulation through the target, d‐VMAT could
potentially minimize small‐ﬁeld dosimetry errors and MLC interplay effects. If
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available, d‐VMAT planning approach is recommended for future clinical lung SBRT
plan optimization.
KEY WORDS

DCA‐based VMAT, FFF‐beam, lung SBRT, single dose

1 | INTRODUCTION

(30 Gy in 1 fraction) using non‐coplanar VMAT lung SBRT plan has
not yet been reported.

The use of stereotactic body radiation therapy (SBRT) has become a

As part of SBRT commissioning of Eclipse TPS (Version 15.6), it

standard curative treatment for medically inoperable early‐staged

is important to stress the importance of investigating new planning

non‐small‐cell lung cancer (NSCLC) patients providing a high cure

features to provide the highest quality and most accurate plan. Dose

rate and minimal treatment‐related toxicity.1‐5 For the selected

to radiosensitive non‐target OAR is a major concern in VMAT lung

peripherally located NSCLC patients, single dose of lung SBRT has

SBRT treatments,32,33 speciﬁcally while delivering a single‐large frac-

become a curative‐intent treatment option as shown by the random-

tion dose as described here. Herein, we have retrospectively evalu-

ized clinical trials.6‐13 Most recently, clinical use of ﬂattening ﬁlter

ated 10 consecutive early‐stage NSCLC patient's plans who

free (FFF) beams has been of interest in delivering lung SBRT treat-

underwent a single dose of VMAT lung SBRT treatment in our clinic.

ments due to dosimetric advantages compared to a ﬂattened

For comparison, the clinical VMAT plans were re‐optimized using a

beam.14‐18 FFF beams can signiﬁcantly reduce beam‐on time due to

DCA‐based VMAT (d‐VMAT) planning approach with identical beam

their higher dose rates, resulting in better patient compliance, poten-

geometry, dose calculation algorithm, grid size, planning objectives,

tially reducing dose delivery uncertainty due to less intrafraction

and parameters. The d‐VMAT plans utilized DCA‐based dose with

motion error and reduction in out‐of‐ﬁeld dose with less head scat-

the highest strength of ﬁeld aperture‐shape control priority before

ter and electron contamination.14‐16

VMAT optimization; therefore, less beam modulation through the

A single‐large dose of 30 Gy in one fraction lung SBRT treatment

target is expected. The original clinical VMAT plans and re‐optimized

is an extreme form of hypofractionation dosing schemata used in

d‐VMAT plans were compared via lung SBRT protocol compliance

our clinic for extracranial lesions where the dose calculation accuracy

criteria for the target conformity, intermediate dose‐spillage, and

could potentially suffer by tumor size, tumor location, and the pres-

dose to OAR per RTOG requirements.6 Furthermore, treatment

ence of tissue heterogeneity in the lung. Utilizing volumetric modu-

delivery efﬁciency and accuracy were reported.

lated arc therapy (VMAT) with FFF‐beams17,18 resulted in better
tumor dose coverage and faster treatment delivery of complex lung
SBRT treatments compared to historically used plans with 8–15 non‐
coplanar ﬁxed ﬁelds or several coplanar DCA ﬁelds with ﬂattened
beams.19‐22 Similar results were observed when compared to linac‐

2 | MATERIALS AND METHODS
2.A | Patient characteristics

based intensity modulated radiation therapy (IMRT), VMAT plans,

After obtaining an institutional review board (IRB) approval from our

helical TomoTherapy, or optimized robotic CyberKnife plans (show-

institution, 10 consecutive Stage I‐II NSCLC patients with peripher-

ing signiﬁcant increases in SBRT treatment times).23‐26 However, for

ally located tumors who underwent a single dose of lung SBRT treat-

a single dose of lung SBRT treatments, highly modulated IMRT/

ments (30 Gy) were included in this study.

VMAT plans are susceptible to delivery uncertainties due to small‐
ﬁeld dosimetry error27 and interplay effects28 due to MLC modulation of multiple beamlets through the target as a function of lung
tumor motion and tissue heterogeneities.

2.B | Imaging and target deﬁnition
All patients were immobilized using Body Pro‐LokTM platform

To minimize these effects, recently, Varian Eclipse treatment

(CIVCO system, Orange City, IA) in the supine position with their

planning system (TPS, Varian Medical Systems, Palo Alto CA, Version

arms above their head using an armrest. The free‐breathing planning

15.1 and beyond)29 has implemented a new multileaf collimator

3D‐CT scan was acquired on a GE Lightspeed 16 slice CT scanner

(MLC) optimization algorithm, called Photon Optimizer (PO). PO

(General

offers a new MLC aperture shaper controller. With this new feature,

512 × 512 pixels at 2.5 mm slice thickness in the axial helical mode.

users can control the ﬁeld aperture shape and create a 3D plan using

Following the 3D‐CT scan, these patients underwent a respiration‐

dynamic conformal arc (DCA) therapy before VMAT optimization.

correlated 4D‐CT scan using the Varian RPM System (version 1.7) in

Although a few investigators have studied the clinical use of PO‐

the same position. The 4D‐CT images were reconstructed in 10

MLC algorithm for VMAT lung SBRT plan optimization,30,31 the dosi-

equally spaced phase bins using an Advantage 4D Workstation (GE

metric impact and treatment delivery complexity of this planning

Medical Systems, San Francisco, CA), where the maximum intensity

approach with a FFF beam in the treatment of single high dose

projection (MIP) images were generated. The regular 3D‐CT and the

Electric

Medical

Systems,

Waukesha,

WI)

with
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MIP images were imported into Eclipse TPS (Version 15.6, Varian

31

(between 30 and 135°) were manually optimized to reduce the MLC

Medical Systems, Palo Alto, CA) and co‐registered for target delin-

tongue‐and‐groove dose leakage throughout the arc rotation on a

eation. An internal target volume (ITV) was created using the 4D‐

per‐patient basis. Additionally, the jaw‐tracking option was used dur-

MIP co‐registered with planning 3D‐CT images. Planning target vol-

ing plan optimization to further minimize out‐of‐ﬁeld dose leakage.

ume (PTV) was generated by adding a 5 mm isotropic margin around

The prescription dose was 30 Gy in 1 fraction to the PTV while cov-

the ITV per RTOG‐0915 recommendation.6 The relevant critical

ering at least 95% of the PTV with prescription dose and ensuring

structures included bilateral lungs excluding the ITV (healthy lung),

that all hot spots (between 120 and 130%) fall within the ITV. All

spinal cord, ribs, heart, trachea/bronchus, esophagus, and skin.

clinical treatment plans were calculated with the advanced AcurosXB

The tumor characteristics are summarized in Table 1 including

(Varian Eclipse TPS, Version 15.6) dose calculation algorithm34‐37 on

tumor size and location. The average ITV derived from the 4D‐CT

the planning 3D‐CT images with heterogeneity corrections with

scan was 6.3 ± 4.9 cc (range: 0.5–15.2 cc). The mean PTV was

1.25 × 1.25 × 1.25 mm3 CGS and the PO‐MLC algorithm. In these

23.3 ± 13.6 cc (range: 6.5–43.8 cc), corresponding to an average

clinical plans, low priority of MLC aperture shape controller was

tumor diameter of 3.4 ± 0.7 cm (range: 2.3–4.3 cm).

used. The dose to medium reporting mode was applied, and the
planning objectives followed the RTOG‐0915 requirements (Arm 1).6

2.C | Clinical VMAT plans and treatment delivery

Before delivering each VMAT‐SBRT plan, a daily quality assurance (QA) check on kilovoltage to megavoltage imaging isocenter

For the 10 consecutive patients, clinically optimal VMAT‐SBRT plans

coincidence was performed, including IsoCal measurement for the

were generated in Eclipse TPS using 3–6 (mean, 4) partial non‐copla-

precise and accurate target localization. IsoCal localization accuracy

nar arcs (with ± 5–10° couch kicks) for a Truebeam Linac (Varian

for our Truebeam Linac was < 0.5 mm. All the QA procedures,

Palo Alto, CA) consisting of standard millennium 120 MLC and

including patient‐speciﬁc QA, were in compliance for SBRT treat-

6 MV‐FFF (1400 MU/min) beam. The isocenter position was set to

ment delivery.5 On the treatment day, patient set up prior to single‐

the geometric center of the PTV. These partial non‐coplanar arcs

dose lung SBRT was performed using SBRT/IGRT protocol;

had an arc length of approximately 200–220°. Collimator angles

registering the pretreatment conebeam CT with the planning CT

5,6

by co‐

scan. Image registration was performed, automatically, based on a
bony landmark region of interest, followed by manual reﬁning perT A B L E 1 Characteristics of lung SBRT patients included in this
study. Prescription was 30 Gy in 1 fraction.
Patient
no.

Tumor
location

PTV diameter, d (cm)

Normal lung
volume (cc)

according to the results of tumor soft tissue registration prior to

2.1

14.8

3.0

3708

within the limits of our departmental lung SBRT protocol guidelines

37.5

4.1

4088

Left upper
lobe

2

Right
lower
lobe

15.2

Right
upper
lobe

3.0

4

Left upper
lobe

4.2

15.2

3.0

4218

5

Right
upper
lobe

12.2

37.6

4.1

5100

6
7

8

treatment delivery. The 6‐DoF couch correction parameters were
for all patients. The patient set up, tumor matching, and treatment
delivery were monitored and veriﬁed by the treating physician and
physicist.

12.8

2.9

3493

2.D | Re‐optimized d‐VMAT plans
For comparison, the standard clinical VMAT plans for all patients
were retrospectively re‐planned (in Eclipse v15.6) using a new feature (MLC aperture controller) with DCA‐based dose calculation followed by VMAT optimization (d‐VMAT). See Fig. 1 for the proposed
workﬂow of this novel approach. For the d‐VMAT plans (with identi-

Left upper
lobe

8.5

Right
upper
lobe

3.1

Right
lower
lobe

tioned using 6 degrees of freedom (6‐DoF) couch corrections

PTV
(cc)

ITV
(cc)

1

3

formed by the treating physician. The patient positon was re‐posi-

35.8

4.0

4456

cal beam geometry), the ﬁrst 2 mm of the MLC aperture around the
PTV is automatically generated and maintained dynamically around

14.4

3.0

5981

the target during arc rotation. The MLC was observed to dynamically
conform to the beam's‐eye‐view (BEV) projections of the PTV for

10

43.8

4.3

5323

each arc. Second, very high priority in the MLC aperture shape controller was selected (a new feature in Eclipse v15.6, PO algorithm in
calculation models) and proceeded to calculate a DCA‐based 3D

9

Left upper
lobe

3.9

14.3

3.0

4584

10

Left upper
lobe

0.5

6.5

2.3

6027

dose distribution. This 3D dose distribution was used as a dose plan
for VMAT optimization. This was followed by VMAT optimization
with identical planning objectives, dose calculation algorithm, grid
size, and convergence mode identical to the original clinical VMAT
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treatment delivery parameters. Dose limits for maximum doses to
spinal cord <14.0 Gy, heart <22.0 Gy, esophagus <15.4 Gy, maxi-

ring structures.

mum point dose and dose to 1 cc of ribs, <30.0 Gy and <22.0 Gy,
maximum point dose and 10 cc of skin <26.0 Gy and <23.0 Gy

2.E | E. Plan evaluation and statistical analysis

were used per single‐dose lung SBRT protocol (RTOG‐0915, Arm 1)

The original clinical VMAT and re‐optimized d‐VMAT plans were

requirements, respectively.

compared using RTOG‐0915 protocol compliance criteria for target
conformity (CI), heterogeneity index (HI), gradient indices (GI), and
dose to OAR. Additionally, delivery efﬁciency and accuracy were
recorded. The DVHs of all treatment plans were evaluated following
RTOG‐0915 high and intermediate dose‐spillage dose parameters:

6

3 | RESULTS
3.A | Target coverage
All plans were acceptable per RTOG‐0915 requirements. Compared

• Conformity index, CI: ratio of prescription isodose volume to the
PTV. CI less than 1.2 is desirable; CI = 1.2–1.5 is acceptable with
minor deviations.
• Gradient index, GI: ratio of 50% prescription isodose volume to
the PTV. GI has to be smaller than 3–6, depending on the PTV.
• Maximum dose at any point 2 cm away from the PTV margin in
any direction, D2cm: D2cm has to be smaller than 50–70%, depending on the PTV size.
• Percentage of normal lung receiving dose equal to 20 Gy or more,
V20: Per protocol, V20 should be less than 10%, V20 less than
15% is acceptable with minor deviations.

to clinical VMAT plans, d‐VMAT plans showed similar tumor conformity, dose heterogeneity, and target coverage; all exhibited no statistical signiﬁcance. However, d‐VMAT plans show better gradient
indices as demonstrated by the values of intermediate dose‐spillage
(GI, D2cm and GD, see Table 2), systematically lower for all patient's
plans.
No major dosimetric differences in terms of dose to OAR were
observed. Both plans achieved the RTOG‐0915 protocol compliance
criteria and were clinically acceptable for stereotactic treatment of
lung lesions. Figure 2 shows an example case of radiosurgical dose
distribution in the axial view through the isocenter plane for an

• Heterogeneity index, HI: HI = Dmax/prescribed dose was used to
evaluate the dose heterogeneity within the PTV.

example lung SBRT patient planned with clinical VMAT (top right

• Gradient distance, GD: GD is the average distance from 100%
prescribed dose to 50% prescribed dose, which indicates how

tighter 50% isodose distribution was obtained with d‐VMAT (see

sharp the dose falls off. The GD is used to evaluate dose sparing

parameters (bottom panel) are shown for the target coverage and

to normal lung volume. The smaller the value of GD, the faster

dose to OAR for clinical VMAT vs d‐VMAT plan, suggesting dosi-

the dose fall‐off around the target.

metrically comparable plans. The PTV size was 35.8 cc (4.0 cm

• Total number of monitor units (MU).
• Modulation factor, MF: ratio of total number of MU to the prescription dose in cGy.
• Beam‐on time, BOT: BOT was recorded during VMAT QA phantom measurement at the machine for both plans.

panel) and d‐VMAT (top left panel). However, clinically desirable
blue isodose lines) compared to the clinical VMAT plan. DVH

diameter). This is a relatively large tumor size in this cohort and
located in the left upper lobe. In this case, the CI, HI, GI, D2cm,
GD, and normal lung V20 Gy were 1.00 vs 1.04, 1.16 vs 1.18, 4.3
vs 4.6, 50.4% vs 52.4%, 1.27 cm vs 1.34 cm, and 1.7% vs 2.0%, d‐
VMAT vs clinical VMAT plan, respectively — all parameters favoring the d‐VMAT plan.

Furthermore, all clinical VMAT and d‐VMAT plans were evaluated for the relative volume of normal lung receiving 10 Gy, dose to
the spinal cord (maximum and 0.35 cc), heart (maximum and 15 cc),

3.B | OAR Sparing

and esophagus (maximum and 5 cc). Since these tumors were

The dosimetric differences (mean and standard deviation) between

peripherally located, the doses to ribs (maximum and 1 cc) and skin

clinical VMAT and d‐VMAT plans for the OAR (spinal cord, heart,

(maximum and 10 cc) were also documented. The mean and stan-

esophagus, trachea/bronchus, ribs, skin, and normal lung) are listed in

dard deviation for each dose metric were compared using two‐tailed

Table 3.

students t‐tests (using an upper bound P value of < 0.05, being sta-

value> 0.05) were found for the most of the evaluated dosimetric

tistically signiﬁcant) for the clinical VMAT vs d‐VMAT plans for all

parameters (excluding dose to ribs and normal lung V20Gy), there is

dosimetric parameters, target coverage, dose tolerances to OAR, and

a clear trend of slightly decreased dose to OAR with d‐VMAT plans

FIG. 1.

Although

statistically

Proposed workﬂow of d‐VMAT treatment planning technique for a single dose of lung SBRT.

insigniﬁcant

differences

(P
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T A B L E 2 Evaluation of target coverage for all 10 lung SBRT patients for both plans.
Target volume

Parameters

PTV

CI

1.04 ± 0.08 (0.98–1.24)

1.02 ± 0.03 (0.99–1.05)

HI

1.24 ± 0.04 (1.18–1.29)

1.22 ± 0.04 (1.16 –1.31)

P = 0.248

GI

4.9 ± 0.9 (3.7–6.5)

4.6 ± 0.7 (3.7–5.7)

P = 0.009

ITV

Clinical VMAT

d‐VMAT

P value
P = 0.102

D2cm (%)

51.1 ± 3.5 (45.7–57.6)

48.6 ± 2.6 (45.3–53.7)

P = 0.002

GD (cm)

1.13 ± 0.13 (0.94–1.34)

1.10 ± 0.13 (0.93–1.27)

P = 0.002

Dmin (Gy)

31.69 ± 1.12 (29.37–33.7)

31.90 ± 1.43 (29.09–34.13)

P = 0.267

Dmax (Gy)

37.03 ± 1.24 (35.28–38.78)

36.90 ± 1.46 (34.90–39.25)

P = 0.604

Dmean (Gy)

34.42 ± 0.97 (33.06–35.46)

34.63 ± 0.89 (33.33–35.51)

P = 0.094

Prescription was 30 Gy in 1 fraction. Mean ± SD (range) was reported. SD = standard deviation. Statistically signiﬁcant P values are highlighted in bold.

F I G . 2 . Comparison of clinical VMAT vs a d‐VMAT plan for the example case #6 described above. The upper panel shows radiosurgical
isodose distributions for the d‐VMAT (left) and clinical VMAT plan (right) — crosshair shows the isocenter location. Better values of CI, HI, GI,
D2cm, GD, and V20Gy were obtained with d‐VMAT plan. A few critical structures shown were ribs, cord, normal lung, heart, esophagus as well
as D2cm ring (orange color contour). The lower panel shows the DVH comparison for the both plans. Triangle shows the clinical VMAT and
square shows the d‐VMAT plan (red, ITV; Pink, PTV; green, ribs; light blue, normal lung; brown, esophagus; blue, heart and dark magenta, skin).
Identical target coverage and similar OAR sparing were achieved with d‐VMAT plan; but, it gave better gradient indices, a shorter treatment
time, and perhaps more accurate treatment delivery.
(see highlighted P values). Despite the dose to ribs and V20 Gy presenting average absolute differences of about 1.0 Gy and 0.1%,

3.C | Treatment delivery efﬁciency and accuracy

these values are well below RTOG guidelines and therefore are not

The improvement of treatment delivery efﬁciency and accuracy is

expected to be clinically signiﬁcant.

directly associated with Eclipse’s new feature of adjustable aperture

34
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T A B L E 3 Evaluation of dose to OAR and treatment delivery efﬁciency for all 10 lung SBRS patients for both plans.
Dose to OAR

Parameters

Spinal cord (Gy)

Dmax

5.1 ± 2.0 (1.0–7.9)

4.9 ± 2.1(1.1–8.1)

P = 0.208

D0.35 cc

4.6 ± 1.8 (0.9–7.2)

4.5 ± 1.9 (1.1–7.4)

P = 0.411

Dmax

5.9 ± 4.9 (0.4–13.7)

5.3 ± 4.3 (0.4–11.2)

P = 0.084

D15 cc

3.6 ± 3.2 (0.2–9.0)

3.4 ± 2.9 (0.2–7.7)

P = 0.187

Dmax

5.8 ± 1.9 (2.3–7.4)

5.6 ± 1.9 (2.2–7.7)

P = 0.209

D5 cc

2.3 ± 1.3 (0.3–4.8)

2.3 ± 1.4 (0.2–5.2)

P = 0.119

Dmax

9.7 ± 5.3 (3.2–18.9)

8.8 ± 4.5 (2.9–16.5)

P = 0.061

D4cc

3.4 ± 2.2 (0.1–7.6)

2.8 ± 2.1 (0.3–6.8)

P = 0.157

Dmax

9.4 ± 2.3 (6.3–13.9)

9.0 ± 1.8 (5.8–12.3)

P = 0.199

Heart/pericardium (Gy)

Esophagus (Gy)

Trachea/bronchus (Gy)

Skin (Gy)

Ribs (Gy)

Normal lung (%)

Clinical VMAT

d‐VMAT

P value

D10 cc

5.6 ± 1.7 (3.9–7.6)

5.4 ± 1.6 (4.1–8.3)

P = 0.115

Dmax

15.5 ± 4.0 (11.3–22.7)

14.1 ± 3.0 (10.1–18.8)

P = 0.006

D1cc

13.7 ± 3.3 (9.8–19.3)

12.7 ± 2.7 (9.4–16.6)

P = 0.009

V20 Gy

1.2 ± 0.5 (0.3–2.0)

1.1 ± 0.5 (0.3–1.9)

P = 0.008

V10 Gy

4.1 ± 1.7 (1.5–6.4)

3.6 ± 1.6 (1.6–5.9)

P = 0.209

Prescription was 30 Gy in 1 fraction. Mean ± SD (range) was reported. SD = standard deviation. Statistically signiﬁcant p values are highlighted in bold.

shape control priority, which allows for DCA‐based dose calculation

patient comfort and potentially reducing errors due to intra‐fraction

before VMAT optimization (Version 15.6). With this new feature,

tumor motion, as well.

less beam modulation through the PTV was obtained and shown

Dose delivery accuracy was accessed by delivering both plans at

here for the same control point (in Fig. 3). In addition to the uncer-

Truebeam Linac in the QA mode using the ArcCHECK device that

tainty of modeling small‐ﬁeld dosimetry, there is a potential concern

was implemented in our clinic (Sun Nuclear Corp., Melbourne, FL,

that the interplay effects between the very high dynamic MLC mod-

Version 8.3) with the center cylindrical insert in place. The dose

ulation and tumor motion can degrade the delivery accuracy com-

delivery accuracy of these clinical VMAT plans, and the correspond-

pared to the calculated values based on static plans. This study does

ing d‐VMAT plans were 91.0 ± 5.5% and 93.1 ± 4.8%, on average,

not quantify the variation of the delivered dose due to the tumor

respectively, with 2%/2 mm global gamma passing rate criteria. In

motion when calculating the dose distributions. However, with

some cases (for small lesions), dose delivery accuracy was improved

d‐VMAT less beam modulation to the projection of the target at

by up to 6% with d‐VMAT plans, suggesting that signiﬁcant dose

each gantry angle (see Fig. 3) and similar MLC patterns were

deviation (P < 0.05) can be seen with highly modulated clinical

obtained for other control points, thus potentially minimizing MLC

VMAT plans compared to d‐VMAT plans.

modulation and reducing the interplay effects. Therefore, the main
beneﬁt of the d‐VMAT plan is the reduced total MU and beam‐on
time required to deliver the same prescription dose.

4 | DISCUSSION

Dose delivery efﬁciency was accessed by comparing total number of MU and estimated beam‐on time while delivering QA plans

A novel and clinically useful lung SBRT planning approach via DCA‐

at the machine. Compared to clinical VMAT plans, d‐VMAT plans

based dose followed by VMAT optimization is presented per RTOG‐

show smaller number of total MU and less beam modulation. Mean

0915 compliance for rapid delivery of a single dose of 30 Gy to lung

values of total MU and MF were 9440 and 3.2 for clinical VMAT

lesions. The new d‐VMAT‐SBRT plans were highly conformal and

plans vs 7030 and 2.34 for d‐VMAT plans. The MF and the beam‐

achieved similar target coverage (see Table 2) compared to clinical

on time for clinical VMAT vs d‐VMAT plans is shown in Fig. 4. For

VMAT plans. For all patients, the d‐VMAT plans provided similar or

the given d‐VMAT plans, the total number of MU was reduced sig-

better OAR (spinal cord, heart, esophagus, trachea/bronchus, ribs,

niﬁcantly (by a factor of 1.35, on average, and systematically lower

and skin, see Table 3) sparing and were well below protocol dose

for all patients) while using DCA‐based dose before VMAT plan

requirements. The d‐VMAT plans required less total number of MU

optimization, suggesting that the d‐VMAT plan had smaller MF

to deliver the same total prescribed dose due to less beam modula-

(P < 0.001). Because of this, the average beam‐on time for d‐VMAT

tion across the target. Therefore, the beam‐on time was reduced sig-

plan was 1.75 min less (P < 0.001) (maximum up to 2.52 min) than

niﬁcantly (average beam‐on time 5.02 min) demonstrating the

clinical VMAT plan (mean value, 6.74 min) due to less beam modu-

efﬁciency of d‐VMAT plans for a single dose of lung SBRT treat-

lation through the target. With d‐VMAT plan, single dose of 30 Gy

ments in this group of patients. With d‐VMAT plans, the beam‐on

to lung lesion can be delivered in 5 min. The lower beam‐on time

time can be reduced by 35–40% compared with clinical VMAT (aver-

will reduce the time the patient is on the table, thus improving

age BOT 6.74 min). Furthermore, the treatment delivery accuracy
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F I G . 3 . Comparison of a selected MLC control point (one control point for arc #1 on each plan) between the d‐VMAT and clinical VMAT
plan (same patient shown in Fig. 1). The d‐VMAT MLC pattern (left panel) conforms to the PTV (pink) with less modulation while the majority
of the PTV is under the MLC block, due to highly modulated MLC pattern, in the clinical VMAT plan (see, right panel). Although both plans
provided similar target coverage and dose to OAR, d‐VMAT plan provided better gradient indices and delivered treatment much faster and
more accurate due to less MLC modulation across the PTV.

F I G . 4 . Left panel: MF for clinical VMAT vs d‐VMAT plans for all 10 patients treated with a single dose of 30 Gy to lung lesions. Mean
values of MF for clinical VMAT and d‐VMAT plans were 3.15 ± 0.55 (range: 2.0–3.88) and 2.34 ± 0.39 (range: 1.55–2.75), respectively. Right
panel: The corresponding BOT for clinical VMAT vs d‐VMAT plans. Mean values of BOT for clinical VMAT vs d‐VMAT plans were
6.74 ± 1.18 min (range: 4.29–8.32 min) and 5.02 ± 0.83 min (range: 3.33–5.89 min) respectively, with d‐VMAT plans signiﬁcantly improving the
beam‐on time.
was improved signiﬁcantly (see Table 4) with measurements analyzed

located lung cancer patients. The 4π algorithm used up to 30 opti-

at 2%/2 mm gamma passing criteria.

mized coplanar/non‐coplanar ﬁelds. In their study, it was concluded
38

that compared to IMRT and VMAT, the 4π plans gave signiﬁcantly

from UCLA compared 4π plans with 7–9 static‐beam IMRT plans and

and consistently better target coverage and critical OAR sparing.

VMAT plans prescribed to 50 Gy in four fractions for 12 centrally

However, the 4π treatment delivery time was not reported. We

For the conformal treatment delivery, a study by Dong et al

T A B L E 4 Comparison of average values of treatment delivery parameters (and range) between clinical VMAT and re‐optimized d‐VMAT plans
for all 10 lung SBRT patients. Mean ± SD (range) was reported. SD = standard deviation.
Beam delivery parameters

Clinical VMAT

d‐VMAT

P value

Total monitor units (MU)

9440 ± 1653 (6000–11641)

7030 ± 1168 (4660–8245)

P < 0.001

Modulation factor (MF)

3.15 ± 0.55 (2.0–3.88)

2.34 ± 0.39 (1.55–2.75)

P < 0.001

Beam‐on time (min)

6.74 ± 1.18 (4.29–8.32)

5.02 ± 0.83 (3.33–5.89)

P < 0.001

91.0 ± 5.5 (86.0–98.6)

93.1 ± 4.8 (86.0–99.3)

P < 0.05

2%/2 mm, γ‐pass rate (%)

Statistically signiﬁcant P values are highlighted in bold.
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believe that delivering 30 c/n‐coplanar ﬁelds to treat lung SBRT

faster treatment delivery is anticipated, potentially beneﬁting

patients would be clinically impractical for current Linac/clinic work-

patients who cannot lie ﬂat in the treatment position for longer time

ﬂows. In contrast, utilizing our d‐VMAT approach with 6MV‐FFF

and reducing intrafraction motion error. Additionally, d‐VMAT mini-

beam can deliver quicker (within a few minutes) and effective cura-

mizes the major concerns over the accuracy of the dose calculation

tive single‐dose SBRT treatments for selected early‐staged NSCLC

and delivery errors for small ﬁelds (beamlets) in areas of tissue inter-

patients.

faces. Moreover, d‐VMAT was observed to minimize the MLC inter-

Potential concerns of changing respiratory motion patterns

play effect as demonstrated with higher pass rates of QA on

between the planning CT simulation and the time of treatment have

phantom measurement (see Table 4). The d‐VMAT planning can be

been studied in the past by many investigators.39‐42 It has been

easily adopted to any other disease sites (including 3–5 fractions

reported in the literature that there were only small changes

lung SBRT) such as stereotactic treatment of brain or any abdominal/

(within ± 3 mm) due to intrafractional and interfractional motion in

pelvis lesions such as liver, pancreas, or adrenal glands SBRT. Due to

lung SBRT treatments. In addition, the mean patient set up time

decreased total number of MU/treatment and smaller beam‐on time

from tumor localization to the end of treatment cone beam CT scan

with d‐VMAT planning approach, deep inspiration breath‐hold lung

was about 40 min.41 It was recommended that a symmetrical 5 mm

SBRT treatments may be of value in future investigations. Moreover,

PTV margin around the ITV was adequate to address these potential

the potential use of MLC shape controller strength in d‐VMAT plan-

set up errors. Furthermore, the interplay effect between the MLC

ning approach for highly irregular large targets that overlapped with

modulation and gantry rotation as a function of tumor motion could

adjacent OAR will be further investigated.

introduce dose blurring on highly modulated VMAT plans, which can
be of another concern for a single high dose of lung SBRT treatments.28 In our study, the average beam‐on time was 5.02 min for

5 | CONCLUSION

single‐fraction lung SBRT treatment with d‐VMAT and 6X‐FFF beam,
decreasing the variation in dose delivery due to coughing or pain

A simple, yet clinically useful d‐VMAT planning technique was pre-

and making geographic miss less likely by improving the patient sta-

sented for a single dose of lung SBRT treatments. The d‐VMAT pro-

bility on the table. Moreover, better delivery accuracy of d‐VMAT

vided excellent plan quality with reduced intermediate dose‐spillage,

plans can improve the major concerns of small‐ﬁled dosimetry errors

reduced dose to normal lung, and other OAR (including rib) and pro-

and MLC interplay effects that persist with highly modulated VMAT

vided faster treatment delivery by signiﬁcantly reducing the beam‐on

plans demonstrated by a higher QA pass rates of our d‐VMAT plans

time when compared to clinical VMAT lung SBRT plans. Furthermore,

delivered in QA phantom measurement.

due to less MLC modulation over the target, d‐VMAT minimized small‐

Other possible fears for lung SBRT treatments are low/intermedi43‐45

ﬁeld dosimetry errors and MLC interplay effects and provided better

normal lung (V20Gy,

QA pass rates. If available, d‐VMAT planning method is recommended

V10Gy, and V5Gy),33,46 and dose to skin.47 For instance, Pettersson

for future clinical lung SBRT plan optimization as it provides a superior

et al43 studied large cohort of 68 NSCLC patients treated 45 Gy in

plan quality with minimal changes to planning workﬂow.

ate dose‐spillage in the chest wall and ribs;

three fractions of lung SBRT. Among the 33 patients with complete
clinical and radiographic follow‐up exceeding 15 months, 13 rib fractures were found in seven patients. In their study, the logistic dose–
response curve exhibited that the risk of radiation‐induced rib fractures following lung SBRT treatments was related to the dose to
2 cc of the rib. For a median follow‐up of 29 months, they showed
that the 2 cc of rib receiving total 27.3 Gy in three fractions had a
5% chance of rib fracture. In the current study, our d‐VMAT plans
provided sharp dose fall off around the target and lower dose tolerances to all OAR (including lower dose to rib, lung, and skin, see
table 3) compared to clinical VMAT plans and all OAR dose metrics
were well below the RTOG criteria. Therefore, we do not anticipate
any acute or late toxicity. However, clinical follow‐up of tumor local‐
control and treatment‐related toxicities of these patients is necessary.
In summary, each d‐VMAT plans were carefully evaluated using
the dosimetric and treatment delivery parameters (including QA
results for 2%/2 mm gamma criteria) listed in Tables 2–4. All parameters were deemed acceptable for both d‐VMAT and clinical VMAT
plans per SBRT protocol requirements suggesting that d‐VMAT plans
are dosimetrically superior to clinical VMAT plans. With d‐VMAT,
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